Fig. 1

Low expression of TMEFF2 mRNA is associated with advanced disease and clinical outcome. a Scatter plot showing TMEFF2 mRNA expression levels in normal, primary and metastatic/CRPC tissue from patients from different prostate cancer cohorts. Expression levels were obtained from Oncomine and compared using a Wilcoxon multiple comparison test. b Kaplan-Meier analysis of biochemical-relapse free survival for patients from the MSKCC prostate cohort stratified by TMEFF2 mRNA expression (n = 11; lowest expression in the cohort) vs. the rest of the patients. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001